Related Experiment Videos
Fenbufen in patients with gastric intolerance
European Journal of Rheumatology and Inflammation
|January 1, 1982
Summary
Fenbufen demonstrates good gastrointestinal tolerability in arthritis patients with a history of NSAID-induced gastric issues. Further controlled studies are recommended to confirm fenbufen
Area of Science:
- Rheumatology
- Gastroenterology
- Pharmacology
Background:
- Non-steroid anti-inflammatory drugs (NSAIDs) are commonly used for arthritis.
- Gastric disturbances and peptic ulceration are known side effects of NSAIDs.
- Patients with a history of gastrointestinal (GI) issues often struggle with NSAID therapy.
Observation:
- An open study evaluated fenbufen in 41 arthritis patients with prior GI problems or peptic ulcers.
- Patients received fenbufen at 600-1200 mg daily for 3-17 months.
- Withdrawal reasons included lack of efficacy (12), non-GI side effects (4), and dyspepsia (3).
Findings:
- Twenty-two patients (54%) continued fenbufen without dyspepsia or GI bleeding.
- The mean treatment duration for these patients was 8.3 months.
- Fenbufen showed potential tolerability in a challenging patient population.
Implications:
- Fenbufen may be a viable NSAID option for arthritis patients with a history of GI intolerance.
- Results support the need for larger, controlled clinical trials to validate fenbufen's safety and efficacy profile.
- This research could inform clinical decisions regarding NSAID selection for patients with GI comorbidities.